Cytokines release inhibition from activated monocytes, and reduction of in-stent neointimal growth in humans

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 242-248

  Pesarini, Gabriele ^a   Amoruso, Angela ^b   Ferrero, Valeria ^a   Bardelli, Claudio ^b   Fresu, Luigia Grazia ^b   Perobelli, Laura ^c   Scappini, Paolo ^c   De Luca, Giuseppe ^b   Brunelleschi, Sandra ^b   Vassanelli, Corrado ^a   Ribichini, Flavio ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Cytokines; Inflammation; Monocytes; Prednisone; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CORTICOSTEROID; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PREDNISONE; PROTON PUMP INHIBITOR; SARTAN DERIVATIVE; THIAZIDE DIURETIC AGENT; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CELL ACTIVATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG ELUTING STENT; DRUG MEGADOSE; FEMALE; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; INTIMA; LOADING DRUG DOSE; MALE; MONOCYTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REDUCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; AGED; CORONARY RESTENOSIS; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS); STENT;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; MONOCYTES; NF-KAPPA B; PREDNISONE; STENTS; TUMOR NECROSIS FACTOR-ALPHA; ANGIOPLASTY, BALLOON, CORONARY;

EID: 77954315357     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.02.004     Document Type: Article

References (21)

1. Welt F.G., Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002, 22:1769-1776.
2. Fukuda D., Shimada K., Tanaka A., et al. Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol 2004, 43:18-23.
3. Liuzzo G., Santamaria M., Biasucci L.M., et al. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein. Evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. J Am Coll Cardiol 2007, 49:185-194.
4. Libby P. Act local, act global, inflammation and the multiplicity of vulnerable coronary plaques. J Am Coll Cardiol 2005, 45:1600-1602.
5. Ribichini F., Joner M., Ferrero V., et al. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J Am Coll Cardiol 2007, 50:176-185.
6. Versaci F., Gaspardone A., Tomai F., et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol 2002, 40:1935-1942.
7. Ribichini F., Tomai F., Ferrero V., et al. Immunosuppressive oral prednisone after percutaneous interventions in patients with multi-vessel coronary artery disease. The IMPRESS-2/MVD study. Eurointervention 2005, 2:173-180.
8. Ferrero V., Ribichini F., Pesarini G., et al. Therapeutic potential of glucocorticoids in the prevention of restenosis after coronary angioplasty. Drugs 2007, 67:1243-1255.
9. Almawi W.Y., Melemedjian O.K. Molecular mechanisms of glucocorticoids antiproliferative effects: antagonism of transcription factor activity by glucocorticoids receptor. J Leukoc Biol 2002, 71:9-15.
10. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-Kappa B activity through induction of I Kappa B synthesis. Science 1995, 270:286-290.
11. Ribichini F., Tomai F., De Luca G., et al. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES)-study design and rationale. J Cardiovasc Med 2009, 10:192-199.
12. Amoruso A., Bardelli C., Gunella G., Ribichini F., Brunelleschi S. A novel activity for substance P: stimulation of peroxisome proliferator-activated receptor-γ in human monocytes and macrophages. Br J Pharmacol 2008, 154:144-152.
13. Lavagno L., Gunella G., Bardelli C., et al. Anti-inflammatory drugs and tumor necrosis factor-α production from monocytes: role of transcription factor NF-kB and implication for rheumatoid arthritis therapy. Eur J Pharmacol 2004, 501:199-208.
14. Gai M.N., Pinilla E., Paulos C., Chavez J., Puelles V., Arancibia A. Determination of prednisolone and prednisone in plasma, whole blood, urine and bound to plasma proteins by high-preformance liquid chromatography. J Chromatogr Sci 2005, 43:201-206.
15. Ferry J.J., Horvath A.M., Bekersky I., Heath E.C., Ryan C.F., Colburn W.A. Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol 1988, 28:81-87.
16. Liuzzo G., Buffon A., Biasucci L.M., et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998, 98:2370-2376.
17. Hojo Y., Ikeda U., Katsuki T., et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 2000, 84:83-87.
18. Szkodzinski J., Blazelonis A., Wilczek K., et al. The role of interleukin-6 and transforming growth factor-beta1 in predicting restenosis within stented infarct-related artery. Int J Immunopathol Pharmacol 2009, 22:493-500.
19. Murayama H., Takahashi M., Takamoto, et al. Deficiency of tumour necrosis factor-alpha and interferon-gamma in bone marrow cells synergistically inhibits neointimal formation following vascular injury. Cardiovasc Res 2008, 80:175-180.
20. Ferrero V., Tomai F., Versaci F., et al. Long-term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated C-reactive protein levels. Eurointervention 2009, 5:250-254.
21. Brunelleschi S., Bardelli C., Amoruso A., et al. Minor polar compounds in extra-virgin olive oil extract (MPC-OOE) inhibits NF-κB translocation in human monocyte/macrophages. Pharmacol Res 2007, 56:542-549.